PDF
ePub
Citation
Print
Abstract
Purpose
Through more than 12 months of follow-up, the efficacy and safety of combination therapy with alpha adrenergic receptor antagonist and anticholinergic agent was investigated retrospectively.
Materials and Methods
This study retrospectively analyzed the data of 84 patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) who were managed with an alpha adrenergic receptor antagonist and anticholinergic agent for at least 12 months between Jan 2007 and Dec 2010. On patients’ first visit to our department, we obtained the patients' demographic data and information about the prostate total volume, serum prostate specific antigen (sPSA), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), and postvoid residual (PVR) of each patient. After 12 months, changes in the above factors and the side-effects of anticholinergic agents were investigated.
Results
The mean age of the patients was 66.1 years and the total observation period after drug administration was an average 20 months; the total sPSA and prostatic volume of patients was 1.8±0.8 ng/dl and 37.3±9.5 g, respectively. Qmax in uroflowmetry was improved after 12 months of medication (changed from 9.0±3.4 to 13.8±4.5 ml/sec; p＜0.001). PVR was increased from 35±22.2 ml to 49.3±37 ml (p＜0.001), but the change was not clinically significant, and no acute urinary retention occurred. The total IPSS score decreased from 21.4±5.1 to 13.3±4.6 (p ＜0.001), the storage score of IPSS decreased from 9.8±2.4 to 5.6±2 (p＜0.001), and the voiding score was decreased from 11.6±3.7 to 7.7±3.2 (p＜0.001). The QoL with IPSS was improved from 4.2±0.8 to 2.8±0.7 (p＜0.001). During the 12 months there were 34 patients (56 cases) of adverse events. However, no serious adverse events were reported.
REFERENCES
1). Gravas S, Melekos MD. Male lower urinary tract symptoms: how do symptoms guide our choice of treatment? Curr Opin Urol. 2009; 19:49–54.
2). Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006; 49:651–8.
3). Chapple CR, Smith D. The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br J Urol. 1994; 73:117–23.
4). Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol. 1979; 121:640–2.
5). Sountoulides P, van Dijk MM, Wijkstra H, de la Rosette JJ, Michel MC. Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol. 2010; 28:3–8.
6). Engström G, Henningsohn L, Walker-Engström ML, Leppert J. Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol. 2006; 40:485–94.
7). Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006; 175:999–1004.
8). Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006; 296:2319–28.
9). Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005; 174:1334–8.
10). Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract. 2008; 62:27–38.
11). Irani J. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: Where do we stand in 2006? Eur Urol. 2006; 50:653–4.
12). Novara G, Galfano A, Ficarra V, Artibani W. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review. Eur Urol. 2006; 50:675–83.
13). Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004; 93:303–10.
14). Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993; 3:335–48.
15). Hong WS, Chung H, Lee JM, Kim TW, Kim HS, Kim HJ, et al. Polypharmacy and central nervous system adverse effects of anticholinergic agents in the men with benign prostate hyperplasia. J Korean Continence Soc. 2007; 11:24–9.
16). Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1997; 104:988–93.
17). Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998; 81:801–10.
18). Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol. 2000; 95:718–21.
19). Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. ow widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87:760–6.
20). Sun YH, Liu ZY, Zhang ZS, Xu CL, Ji JT, Wu YY, et al. Longterm efficacy and safety of tamsulosin hydrochloride for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: data from China. Chin Med J (Engl). 2011; 124:56–60.
21). Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, et al. ALF-ONE Study Group. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int. 2008; 101:847–52.
22). Park CH, Chang HS, Oh BR, Kim HJ, Sul CK, Chung SK, et al. Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a nonblind multicentre korean study. Clin Drug Investig. 2004; 24:41–7.
23). Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003; 169:2253–6.
24). Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc. 2001; 49:700–5.
Table 1.
Baseline characteristics, IPSS, and QoL index before and after combined therapy
XML Download